# Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD

> **NCT00382616** · PHASE2 · COMPLETED · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 90 (—)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Phosphatidylserine-Omega3

## Key facts

- **NCT ID:** NCT00382616
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** 90 (—)
- **Last updated:** 2006-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00382616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00382616, "Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00382616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*